Follow CGSP on Social Media

Listen to the CGSP Podcast

FT: The Evidence From Chile Says Sinovac’s Vaccine is Working

Despite earlier concerns over its low efficacy rate, the Chinese-made Sinovac COVID-19 vaccine appears to be performing well in its largest test to date in Chile, according to the findings by the Financial Times’ Senior Data-Visualization Journalist John Burn-Murdoch.

Sinovac’s 50.4% efficacy rate that was derived from phase three clinical trials in Brazil, related to mild cases only. What Burn-Murdoch’s reporting shows is that the vaccine is successfully protecting people from becoming seriously ill and keeping them out of the intensive care unit.

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.

China, Africa and the Global South... find out what’s happening.

Subscribe today for unlimited access.

What is The China-Global South Project?


The China-Global South Project is passionately independent, non-partisan and does not advocate for any country, company or culture.


A carefully curated selection of the day’s most important China-Global South stories. Updated 24 hours a day by human editors. No bots, no algorithms.


Diverse, often unconventional insights from scholars, analysts, journalists and a variety of stakeholders in the China-Global South discourse.


A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.